SOCIUM
Tokyo
About SOCIUM
SOCIUM is an AI-powered drug discovery and development company focused on first-in-class small molecules. The company currently has a development portfolio of over 23 diseases, including oncology and rare diseases. The company replaces multiple steps in the traditional drug discovery process with an in-silico system using our cutting edge algorithm, established a system to identify the drug discovery target in a few months. By taking a systems biology approach using our Augmented intelligence and Machine Learning – instead of hypothesizing the mechanism of a disease and focusing on only a few related compounds, we profile the entire disease by analyzing various OMICS data.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.4M
- Funding stage: Seed
- Last round: Seed (Oct 2018)
- Website: socium.co.jp
- Phone: +81 03-6869-7996
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Health Care, Machine Learning, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/socium-109936 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.